YOU DESERVE BRAVE SCIENCE Trademark

Trademark Overview


On Wednesday, August 4, 2021, a trademark application was filed for YOU DESERVE BRAVE SCIENCE with the United States Patent and Trademark Office. The USPTO has given the YOU DESERVE BRAVE SCIENCE trademark a serial number of 90864504. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Friday, July 12, 2024. This trademark is owned by Neurocrine Biosciences, Inc.. The YOU DESERVE BRAVE SCIENCE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the diagnosis, prevention and treatment of psychiatric, neurological, endocrine, central nervous system, hormonal, genetic and movement diseases, disorders and conditions; pharmaceutical preparations for the treatment of tardive dyskinesia; pharmaceutical preparations for human use for diagnosis, prevention and treatment of diseases and disorders by gene therapy, namely, Friedreich's ataxia and congenital birth defects; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions, namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia
you deserve brave science

General Information


Serial Number90864504
Word MarkYOU DESERVE BRAVE SCIENCE
Filing DateWednesday, August 4, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateFriday, July 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 7, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for the diagnosis, prevention and treatment of psychiatric, neurological, endocrine, central nervous system, hormonal, genetic and movement diseases, disorders and conditions; pharmaceutical preparations for the treatment of tardive dyskinesia; pharmaceutical preparations for human use for diagnosis, prevention and treatment of diseases and disorders by gene therapy, namely, Friedreich's ataxia and congenital birth defects; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions, namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 29, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNeurocrine Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events


Event DateEvent Description
Tuesday, May 3, 2022ASSIGNED TO EXAMINER
Saturday, August 7, 2021NEW APPLICATION ENTERED
Wednesday, September 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 4, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 18, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 7, 2022PUBLISHED FOR OPPOSITION
Tuesday, June 7, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 2, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 1, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 1, 2023TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, February 1, 2023DIVISIONAL REQUEST RECEIVED
Wednesday, February 1, 2023SOU EXTENSION 1 FILED
Friday, May 19, 2023DIVISIONAL PROCESSING COMPLETE
Monday, March 6, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, April 25, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 19, 2023SOU EXTENSION 1 GRANTED
Saturday, May 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 25, 2023CORRECTED NOA E-MAILED
Monday, July 24, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 24, 2023SOU EXTENSION 2 FILED
Monday, July 24, 2023SOU EXTENSION 2 GRANTED
Thursday, January 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 23, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 23, 2024SOU EXTENSION 3 FILED
Tuesday, January 23, 2024SOU EXTENSION 3 GRANTED
Friday, July 12, 2024SOU TEAS EXTENSION RECEIVED
Friday, July 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 12, 2024SOU EXTENSION 4 FILED
Friday, July 12, 2024SOU EXTENSION 4 GRANTED